Ziccum AB (publ) completes directed share issue of SEK 38.8 million to accelerate development of temperature-stable vaccines

The Board of Directors of Ziccum AB ("Ziccum" or "the Company") today resolved and successfully implemented a private placement of a total of 2,216,815 shares to a limited number of qualified private investors, supported by authorization from Annual General Meeting on June 16. Ziccum is allocated SEK 38.8 million before issue costs. The capital ensures the Company's long-term financing and enables accelerated development of production of temperature-stable vaccines.

The subscription price in the directed share issue has been determined through a so-called accelerated bookbuilding process and amounts to SEK 17.50 per share, corresponding to a discount of 8.10 percent compared to the volume-weighted average price for the share during a period of 10 trading days up to and including June 23, 2020. The Board of Directors assesses that, due to the bookbuilding process, the directed share issue was carried out on market terms.

The Board of Directors has decided to deviate from the shareholders' preferential right in order to provide the Company with capital in a time- and cost-effective way to accelerate the development and commercialization of the Company's unique method for producing dry formulated and temperature-stable vaccines.

Ziccum is developing a method that makes it possible to produce temperature-stable vaccines in a unique and effective way. The company has already announced several industrial collaborations around the technology as well as patent applications for, for example, vaccines based on Adenovirus and viruses from the measles family. In addition, the vaccine market is in a very expansionary phase in the wake of the ongoing pandemic. By increasing the pace of development of production for commercial purposes, the lead time in ongoing and new collaborative projects can be significantly shortened and Ziccum can potentially make greater claims for milestones and royalties in future commercial agreements. The Board is of the opinion that the value of Ziccum's offering to companies that develop and produce vaccines will be strengthened as technical and regulatory risks are minimized.

Ziccum CEO Göran Conradson: "We are developing a unique and potentially groundbreaking production methodology that could fundamentally change the availability of vaccines worldwide. Based on a rapidly growing number of laboratory experiments under our own control and with partners, we can conclude that LaminarPace works very well. We will now invest in being able to offer ready-made production solutions faster, to manage dry formulated vaccines, so shortening the time to market. Above all, we want to accelerate the development of temperature-stable vaccines that can save the lives of millions of children every year."

The directed share issue will have a dilution effect of approximately 23.1 percent of the number of shares and votes in the Company. Through the directed share issue, the number of outstanding shares increases by 2,216,815 shares, from 7,389,385 shares to 9,606,200 shares. The company's share capital increases by approximately SEK 369,469.17 from approximately SEK 1,231,564.17 to approximately SEK 1,601,033.33.

Advisor

Ziccum has engaged Erik Panser Bank and Fredersen Advokatbyrå as financial and legal advisors in connection with the directed share issue.

Important information

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL OR COUNTER TO CURRENT REGULATIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES IN ZICCUM

The announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Ziccum in any jurisdiction.

This press release does not constitute and does not form part of an offer or solicitation to buy or subscribe for securities in the United States. The securities referred to here may not be sold in the United States without being registered or exempt from registration under the 1933 U.S. Securities Act, as amended, and may not be offered or sold in the United States without being registered or are exempt from registration or are included in a transaction that is not covered by registration under the Securities Act. There is no intention to register any securities referred to here in the United States or to make a public offer regarding the securities in the United States. The information in this press release may not be published, published, copied or distributed, directly or indirectly, in whole or in part, in or to the United States, Canada, Japan, South Africa or Australia or any other jurisdiction where the disclosure, publication or distribution of the information would not be in effect laws and regulations or would require a prospectus, registration or other measures than those required by Swedish law. Measures contrary to this instruction may constitute a violation of applicable securities law.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Ziccum has not accepted any offer to the public of securities in any Member State of the EEA and no prospectus has been prepared or will be produced in connection with the rights issue. In each EEA Member State, this Communication is only addressed to "qualified investors" in that Member State as defined in the Prospectus Regulation.

In the United Kingdom, this document and other material is distributed and directed in relation to the securities described herein only, and any investment or investment activity to which this document relates is only available to and will be exploited only by "qualified investors" who are (i) persons with professional experience in matters relating to investment which fall within the definition of "investment professionals" in Article 19 (5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("the Order"); or (ii) persons of high net worth covered by Article 49 (2) (a) – (d) of the Order (all such persons collectively referred to as "relevant persons"). In the UK, any investment or investment to which this Communication refers is available only and will involve only relevant persons. Persons who are not relevant persons should not take action based on this press release and will not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect Ziccum's intentions, assessments or current expectations and goals for Ziccum's future operations, financial situation, development, liquidity, earnings, prospects, expected growth, strategies and opportunities, and the markets in which Ziccum operates. Forward-looking statements are statements that are not historical facts and can be identified by containing words such as "believe", "expect", "anticipate", "intend", "can", "plan", "estimate", "should" , "Could", "aim" or "maybe" or, in each case, negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which in turn are based on additional assumptions. Although Ziccum believes that the expectations reflected in these forward-looking statements are reasonable, it does not provide any assurances that they will occur or prove to be accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or results may differ materially from those presented in the forward-looking statements which are the result of many factors. Such risks, uncertainties, unforeseen events, and other important factors may cause actual events to differ materially from the expectations expressed or implied herein by such forward-looking statements. Ziccum does not guarantee that the assumptions behind the forward-looking statements in this press release are free from errors and assumes no responsibility for the future fulfillment of the statements made in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Readers of this press release should not unduly rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release are provided only on the day of this press release and are subject to change without notice. Neither Ziccum nor anyone else undertakes any obligation to review, update, confirm or publish any revisions to forward-looking statements to reflect events arising or circumstances arising in relation to the contents of this press release.

For more information on Ziccum, please contact:

Göran Conradson: CEO 
Email:
conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones. 

The above is information that Ziccum is required to publish according to the EU Market Abuse Regulations. The information was submitted for publication on June 24, 2020, through the authority of the above contact person.

ZICCUM AB (publ) Flagging message (regulatory)

(Lund, Sweden, April 23, 2020.) The company's largest owner, Inhalation Sciences Sweden AB (publ) ("ISAB"), today announced the sale of 1,790,000 shares in Ziccum AB (publ) ("Ziccum"), corresponding to ISAB's entire holding in Ziccum. The sale was made outside the market via Penser Bank on behalf of ISAB to stakeholders with a long-term interest in Ziccum. The buyers include three members of Ziccum AB's Board of Directors, Kristian Kierkegaard, Mikaela Bruhammar and Fredrik Sjövall.

Since the spin-off and listing of Ziccum, ISAB has been a passive shareholder in Ziccum, and the sale is in line with what both companies have previously communicated about ISAB's ambition to divest its holding.

Ziccum's CEO Göran Conradson: "We can see that the market showed great interest in ISAB's sale of sits hares in Ziccum. We're very pleased to add strong, long-term investors in Ziccum."

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: 
conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company's patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets-and open up new ones.

ZICCUM AB First Quarter Report, Q1 2020

Summary of Interim First Quarter Report 2020: Further industrial and NGO collaborations.

Summary of Interim First Quarter Report 2020

Ziccum announced a further, third collaboration with an industrial partner that is developing a new, more effective method of producing measles and rubella vaccines. The goal is to both significantly reduce the cost, and increase the availability, of these childhood vaccines. We have also signed a confidentiality agreement with an important non-governmental organization (NGO) for further and more detailed discussions about how technology can help the most vulnerable.

JanuaryMarch 2020

Net sales SEK 0 thousand (0)
Operating profit SEK -3 980 thousand (-1 689)
Earnings per share before and after dilution SEK -0.55 SEK (-0.28)

CEO Statement

Vaccination is, and has always been, one of the best ways to prevent pandemics and epidemics. The need for vaccination has never been greater than it is today. New global travelling habits, population growth, climate change, rapid urbanization-they all increase the potential risk of epidemics and pandemics. And children are the most vulnerable: one in five children still do not receive adequate vaccine protection. Approx. 1.5 million children die every year from vaccine-preventable diseases.

Our most recently announced collaboration (March 26) is with an industrial partner who is developing a new production process for measles and rubella vaccine. The number of measles cases more than doubled in 2018, with children under five having the highest mortality. According to UNICEF, measles vaccination has to increase significantly. In order to prevent more measles outbreaks, the WHO recommends a vaccination rate of 95% for all newborn babies, especially the two doses needed for full protection. The current vaccination rate is 85% for the first dose, but only 67% for the second.

UNICEF points out that globally 450 million doses of measles vaccines are needed, yet presently only 270 million doses a year are produced. This is explained by a lack of production capacity, and the destruction and waste of vccines during transport and handling. At present, vaccines require extensive, costly and extensive refrigerated transport to reach the poor, usually hot and often extremely inaccessible places where they are needed most.

UNICEF estimated the total measles vaccine market to be worth 450 million USD in 2018.

Ziccum has a globally unique, patented technology – LaminarPaceTM – that allows us to produce vaccines in dry powder form, which is not practically possible or economically feasible using conventional vaccine formulation technologies. The benefits of dry powder vaccines are many. Dry powder formulation increases the stability and shelflife of the vaccine, so facilitating the entire supply chain from factory to field patient and enabling vaccines to reach new sites where, for example, refrigeration and freezer storage is a major challenge. The overall result is more people vaccinated, at a lower cost.

Despite Covid-19, our own work in the lab continues, as we develop new formulations and carry out stability analyses that can form the basis for new patent applications and partnerships. The further development of our production system, focusing on preparing for future production of vaccines on a commercial scale, is also proceeding according to plan, without being impacted by Covid-19. We continue to develop our commercial work by collaborating with a range of policy groups that are working to improve vaccination coverage worldwide. We have, for example, signed a confidentiality agreement with a vaccine NGO in order to deepen discussions. European vaccine manufacturers now know us, and we are starting to make contact with American vaccine developers. The dialogue with our current partners, including our two previous evaluation agreements, also continues but we can state that the current coronavirus pandemic will lead to delays as these organizations are currently suffering from limited access to their labs.

In summary, we are well on our way to delivering this year's goals on target, whilst positioning Ziccum well for an exciting future in an industry that will have a strong focus for a long time to come – we have entered into three evaluation agreements with industrial players to develop stable, dry powder vaccine formulations, we have a world-leading academic partner who will continue to strengthen our technology and patent portfolio, and we have processes and projects in place to develop a commercial version of our product. We now look forward to maintaining a continued high rate of development for our competitive technology, enabling us to generate new. significant patents and create exceptional value for our shareholders.

Lund, April 17, 2020

Göran Conradson

CEO, Ziccum AB

 READ THE WHOLE REPORT, IN SWEDISH, HERE

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: 
conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company's patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets-and open up new ones.

This press release has been submitted for publication by the company's CEO at. 08.00 (CET) on April 16 2020.

ZICCUM signs Letter of Intent to explore integrating Ziccum technology into innovative vaccine biomanufacturing line

(Lund, Sweden, March 26, 2020) An innovative vaccine biomanufacturer has formally declared its intention to explore incorporating Ziccum technology into its manufacture of measles and rubella vaccines, with the ultimate aim of reducing the cost of vaccines for children.

The agreement is to begin exploring the incorporation of LaminarPace, Ziccum's dry powder drug formulation tool, into the manufacture of measles and rubella vaccines. By formulating vaccines as dry powders, LaminarPace could eliminate the need for Cold Chain refrigerated infrastructure in supply chains. Dry powder vaccines would be faster, simpler and more cost-effective to transport, reaching more children in fragile, poor, war-torn and remote regions.

With measles cases more than doubling in 2018, and the vast majority of measles deaths being children under 5 yrs. (1), UNICEF identifies increased measles immunisation as an urgent priority. UNICEF points out that the current global demand for measles vaccines (450 million doses) significantly exceeds the number of supplied doses needed (270 million – two per 135 million children). UNICEF says this is because of "coverage and wastage rates" (2). Currently, vaccine formulations require extensive refrigerated cold chains even in poor, often hot remote areas to reach full coverage. Ziccum's air drying vaccine technology LaminarPace, formulates vaccines that can be shipped as stable, temperature-resistant dry powders-reducing waste and coverage costs and increasing access.

UNICEF recognizes that "new market entrants (to vaccine manufacture) are needed to improve market health, diversity, supply and reduce supply risk". UNICEF anticipates issuing a new tender for vaccine manufactures in 2020, for supply in 2021.

Ziccum CEO Göran Conradson: "This is a landmark agreement that could ultimately transform global access to vaccines. It's never been more urgent to tackle under-vaccination. Measles cases more than doubled in 2018, and 2019 data already show a three-fold increase in the number of cases compared to the same time last year (3). If the US had Samoa's current number of measles cases, 7 million Americans would be infected (4) We're proud to be taking this brave and timely initiative with our partners as part of our shared commitment to increasing global access to vaccines".

Footnotes

  1. Washington Post 6 December 2019
  2. UNICEF: Measles Monovalent and Measles and Rubella Combination Vaccines: Supply and Demand Update, UNICEF Supply Division, August 2019 
  1. Washington Post 6 December 2019
  2. UNICEF 5 December 2019

 

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company's patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets-and open up new ones.

This press release has been submitted for publication by the company's CEO on March 26, 2020 according to EU Market Abuse Regulations.

Ziccum AB (publ) Year-end report January 1 – December 31, 2019

LUND, SWEDEN – 13 February 2020. Ziccum AB (publ), summary of the year-end report – fourth quarter 2019: Ziccum is well on its way to delivering what we promised when listing our share – to start three projects during the year to develop stable, dry vaccine formulations as well as biological drugs.

CEO Statement

Ziccum has a unique, patented technology – LaminarPaceTM – that enables us to manufacture biological drugs in dry form. In principle, dry form is always sought after in the development of new drugs and the benefits are many. It increases the stability of the product and thus its service life, it facilitates the entire transport and supply chain from factory to patient and it enables distribution of medicines to new places where, for example, refrigeration and freezer storage is a major challenge. This means that patients who do not have treatment or treat themselves in their homes can have access to safer and more effective vaccines and medicines.

In 2019, we filed two patent applications, one on a very important component in the development of new vaccines – Adenovirus, and on viruses in the same family as the measles virus. As a result, several industrial players have taken note of our technology. We have also announced that we have entered into agreements with two of these companies for the purpose of evaluating LaminarPaceTM in combination with their particular projects. In both collaborative projects, we have delivered test materials dried in our LaminarPace technology and at present, each counterparty is working on evaluating these materials in their own models and methods. When this is clear, we look forward to discussing the next step with each company. Our hope is that this will happen in the first half of this year. Further patent applications and industrial collaborations continue to be the cornerstones of our business.

We continue to work in-depth with a consortium of several important players – both industrial and academic – including Aix-Marseille University, France, which has the opportunity to work on virtually all vaccines and pathogenic viruses on its own premises. There is a common strong interest in developing temperature-stable formulations together, which gives us further opportunities. This new partnership will provide us with many benefits as well as a significant extension of our resources. During Q1, we will deliver a system to their high-security laboratory to further develop new temperature-stable formulations. Work developing LaminarPaceTM systems adapted for large-scale industrial production of biological drugs and vaccines is proceeding according to plan. This will continue to be a very important project in 2020, better positioning us for future partnership discussions.

In 2020, we will develop our commercial work by collaborating with various policy groups that are working to improve the uptake of vaccinations around the world, so increasing awareness of the importance of our method. European manufacturing vaccine companies know us well and in 2020 we will expand our work with overseas manufacturers.

In conclusion, we are well on our way to delivering on everything we promised when listing our company – we have three pilot studies ongoing within the year to develop stable, dry vaccine formulations and biological drugs. We now look forward to maintaining a continued high rate of development of our competitive offering, where we can generate significant benefits for patients as well as create value for our shareholders.

Oct-Dec 2019

· Net sales SEK 0,0 (35)

· Operating income SEK -3,344 thousand (-1,734)

· Earnings per share before and after dilution SEK -0.56 (-0.32)

Jan-Dec 2019

· Net sales SEK 0,0 (227)

· Operating profit SEK -8,721 thousand (-4,210)

· Earnings per share before and after dilution SEK -1.45 (-1.27)

Significant events during fourth quarter 2019

In early October, an agreement was concluded for evaluation with a global pharmaceutical and vaccine company, where together we will evaluate Ziccum"s technology to generate stable and temperature-stable vaccines.

A new patent application for a new temperature-stable formulation of virus in the same family as measles was filed in December 2019.

Collaboration with a world-leading virology group in Marseille was started.

We have initiated work on impact work by international policy groups on vaccine use.

As of the balance sheet date (which was the last subscription day), outstanding warrants had been subscribed for 92.6 percent of the total number of outstanding warrants, which corresponds to approximately SEK 13.9 million.

Significant events during the reporting period (Jan-Dec) 2019

Ziccum reported on January 10, 2019 that the company filed a patent application for Adenovirus with dry and temperature-stable formulation which meets WHO"s requirements for CTC status.

The dry formulation (the "powder") generated by Ziccum"s technology in LaminarPace ™ dissolves rapidly upon the addition of sterile water, after which vaccination or treatment can be performed.

Final liquidity from EU support for FORMBECC was received during the second quarter amounting to approximately SEK 315 thousand.

Ziccum has been granted SEK 200,000 in research grants from Vinnova. The research grant will be used to evaluate Ziccum"s method for developing dry preparations of vaccines.

Ziccum has hired additional staff with expertise in the formulation of vaccines.

We received a special invitation to attend the Global Vaccine Summit in Brussels where several important contacts were made.

Ziccum, on behalf of a vaccine development company, has conducted a feasibility study on the development of stable vaccines. The work is underway and the samples have been sent back for further evaluation. In the second collaboration, we have delivered dried material. Respective collaborator are evaluating the material with their own methods and models. Results from both collaborations are expected to come in the first half of 2020.

A second patent application has been filed for a group of viruses belonging to the measles virus family.

We have initiated collaboration with a French virology group at Aix-Marseille University. A LaminarPace system will be placed in their BSL3 (BioSafety Level 3) facility during the first quarter, for further development of new formulations. The group is also a co-ordinator of a large EU-funded global collaboration on the distribution of various virus strains for research, development and as reference material in diagnostics and for vaccine companies, EVAg, European Virus Archive Global.

We have begun the impact work of international policy groups to improve the uptake of vaccinations. The European vaccine companies know us well.

Significant events after the reporting period

The issue proceeds relating to warrants amounted to approximately SEK 13.9 million, which were added to the company in January 2020. The issue was registered by the Swedish Companies Registration Office on 2020-01-14.

Otherwise, no significant events have occurred since the reporting period.

Lund, February 13, 2020

Göran Conradson

CEO

For more information on Ziccum, please contact:

Göran Conradson: CEO 
Email:
conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum AB

Ziccum AB develops and commercializes the patented spray-drying instrument LaminarPace®. LaminarPace is an innovative, CE-labelled instrument that dries small amounts of drug substances with very low losses. The vast majority of pharmaceutical projects prefer substances in dry powder form, as it increases their stability, durability and simplifies logistics and transportation. LaminarPace is also unique in its ability to handle temperature-sensitive materials such as proteins and peptides.

The information above was provided by Ziccum AB (publ) through the above contact person, for publication on 08.00 February 13, 2020.

ZICCUM AB submits patent application for new temperature-stable, dry-powder formulation of virus belonging to same family as Measles

Lund 20 December 2019. Temperature demands on vaccines are getting tougher, as underimmunisation becomes more urgent. As part of  the WHO"s strategic mission to vaccinate more people worldwide, it now demands that vaccines must be stored at +40 degrees C for at least three days in order to earn CTC (Controlled Temperature Chain) approval (1). Ziccum is now applying for one patent that will cover a range of dry-formulated viruses and vaccines that can meet CTC demands, including new formulations of measles vaccines.

Ziccum"s new, active, temperature-stable, dry-powder formulated viruses can be stored at +40 degrees C for at least one week with no loss of active ingredient, not only meeting, but surpassing, WHO CTC requirements. The formulation is unique, according to the company, and could lead to a significant global increase in the number of people who can be vaccinated. The company, which dries liquid viruses and vaccines using its LaminarPace TM drying technology, has now submitted a formal patent application for the new formulation. 

Cracking the Cold Chain

"This solves a problem no one has been able to solve before," says CEO Göran Conradson. "We can formulate vaccines that are safe and stable to transport, and will not need costly refrigeration equipment during the crucial last mile to reach the people who need them most. Under-immunization is an urgent priority right now. For example-if the US had Samoa"s current number of measles cases, 7 M Americans would be infected. Dry formulations of vaccines could play an important part in helping meet the urgent need for better vaccination coverage worldwide."

Measles vaccines urgent – UNICEF

With measles cases more than doubling in 2018, and the vast majority of measles deaths being children under 5 yrs (2), UNICEF identifies increased measles immunisation as a particularly urgent priority. To prevent future measles outbreaks the WHO recommends 95% immunization coverage worldwide. UNICEF points out that globally 136 million children require two measles doses a year, which in year 2017 equated into a global demand for approximately 450 million doses for all country routine immunization programmes, taking into account coverage and wastage rates. Indicating 40% wastages. UNICEF supplied approximately 65% of 270 million doses at a value of USD 125,7(3).

"Vaccines formulated as dry powders would require no refrigerated cold chains to reach full coverage-even in remote and hot areas" Conradson says. "And would constitute an exceptionally low-waste vaccine solution."

  1. https://www.who.int/immunization/programmes_systems/supply_chain/ctc/en/ 
  2. Washington Post 6 December 2019
  3. UNICEF: Measles Monovalent and Measles and Rubella Combination Vaccines: Supply and Demand Update, UNICEF Supply Division, August 2019 

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: 
conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company"s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets-and open up new ones.

This press release has been submitted for publication by the company"s CEO on 20 December at 1400.

ZICCUM AB engages Emerging Viral Diseases unit of Aix-Marseille University to develop dry viruses and vaccines, strengthening Ziccum”s future IP portfolio

Lund, 19th December 2019. The Emerging Virus Unit (Unité des Virus Émergents) is one of the world"s leading virology laboratories. Ziccum has now engaged UVE to use Ziccum"s technology to develop and formulate vaccines and viruses as dry powders, boosting global access to them and making them significantly faster and cheaper to transport. This collaboration will significantly strengthen Ziccum"s IP portfolio.

"Underimmunisation has never been more urgent" says Ziccum CEO Göran Conradson "this decision by Unité des virus émergents (UVE) to collaborate and develop the use of our technology to see if it can make virus and vaccine materials easier and more cost-effective to transport worldwide is far-sighted and timely. We believe it could ultimately play a part in making vaccines more globally accessible."

UVE is one of the world"s leading virology labs and together with its partners they prepare and ship reference materials for vaccine development, academic research and diagnosis worldwide. Ziccum has engaged UVE in the company"s development of new dry versions of vaccines in the highly advanced laboratories (BSL3) available at UVE.

During an initial 18 month period UVE will formulate and test a wide range of viruses and vaccines as dry powders with an ultimate goal to make them transportable without any need for cold chain refrigeration.

"This gives us much prized access to UVE"s world-leading, high-safety BSL3 labs. That is a rare asset and will secure data and IP for Ziccum", continues Göran Conradson.

Since 2014 UVE has also coordinated the European Commission sponsored European Vaccine archive, which in 2020 will be a global consortium with 46 partner and associated partner labs across 21 countries. UVE will use LaminarPace to carry out stability testing, temperature analyses and more on the new dry-form viruses and vaccines.

Professor Remi Charrel, scientific head at UVE: "Ziccum technology has the potential to significantly improve the storage and shipping of virus samples, two key steps to promoting the distribution of high-quality biological material to support research in virology."

Ziccum CEO Göran Conradson:  "The contract for the engagement with AMU has already been signed, with implementation pending a successful outcome to Ziccum"s ZICC TO 1 subscription option. A new range of tough, dry powder virus and vaccine materials that is faster and more cost-effective to transport could be a key part of solving the underimmunisation crisis. We"re very excited to move this project forward."

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: 
conradson@ziccum.com

Mob: +46 709 61 55 99

 

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company"s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets-and open up new ones.

Market Notice 310/19 – Last day of trading in Ziccum AB subscription option ZICC TO 1

Last day of trading in the company’s subscription option, ZICC TO 1, is  
December 20, 2019. 

Information about the subscription option: 
Shortname: ZICC TO 1 
ISIN: SE0011641950 
Orderbook-ID: 4NGA 
CFI: RMXXXX 
FISN: ZICCUM/OPT RTS 20191231 
Last day of trading: December 20, 2019 

Stockholm December 2, 2019 

Spotlight Stock Market 
08-511 68?000   
trading@spotlightstockmarket.com  

 

ZICCUM AB Third Quarter Report, 2019

Summary of Interim Third Quarter Report 2019: Ziccum well on way to delivering promises made during listing.

Summary of interim report – third quarter 2019

Ziccum is well on its way to delivering on the promises made when we first listed our stock – that during the year we would start three projects to develop stable, dry vaccines and biological drugs. So far during 2019 we have entered into two industrial collaborations, one with a global pharmaceutical company. We have also filed a patent application for a very important component in the development of new vaccines – Adenovirus. We continue to work with leading industrial and academic players to further develop the technology and adapt it for large-scale industrial production of biological drugs and vaccines. This is to position us for future discussions about partnership.

Jul-Sep 2019

Net sales KSEK 0 (0)

Operating income KSEK -1,380 (-1,714)

Earnings per share before and after dilution SEK -0.23

(-0.62)

Jan-Sep 2019

Net sales KSEK 0 (192)

Operating profit KSEK -5,378 (-2,442)

Earnings per share before and after dilution SEK -0.90

(-0.93)

Significant events during the third quarter of 2019

  • Ziccum has hired additional staff with expertise in the formulation of vaccines
  • We received a special invitation to attend the Global Vaccine Summit in Brussels where several important new contacts were made
  • Ziccum, on behalf of a vaccine development company, will conduct a feasibility study development of stable vaccines. The preliminary study does not entail any financial compensation at this stage but aims to investigate the compatibility of Ziccum air drying capability with the company"s new formulation

Significant events during the reporting period (Jan-Sep) 2019

  • On January 10, 2019, Ziccum reported that the company had filed a patent application for its dry and temperature-stable formulation, which meets the WHO"s requirements for CTC status. The dry formulation (the "powder") generated by Ziccum"s technology in LaminarPace ™ dissolves quickly when sterile water is added and then vaccination or treatment can be performed
  • Final payment from the EU support for FORMBECC was received during the second quarter amounting to approximately SEK 315 thousand
  • Ziccum has been granted SEK 200,000 in research grants from Vinnova. The research grant should used to evaluate Ziccum"s method for preparing dry preparations of vaccines

Significant events after the reporting period

  • At the beginning of October, an agreement was concluded for evaluation with a global drug and vaccine company, where together we evaluate Ziccum"s technology to generate stable and temperature-stable vaccines

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

This press release has been submitted for publication by the company"s CEO at. 08.00 (CET) on November 7, 2019.

Posts navigation

1 2 3 15 16 17 18 19 20